As per terms of the merger deal, Cambrex shareholders will secure $60 (£49.3) in cash for each share of Cambrex common stock, representing a 47.1% premium to its
The post Permira to buy small molecule company Cambrex for £1.97bn appeared first on Pharmaceutical Business review.
Original Article: Permira to buy small molecule company Cambrex for £1.97bn